Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles (Q24250231)

4

0 references

Fulco Van der Veen

3

0 references

author name string

Lars W Westergaard

1

0 references

Patrick MM Bossuyt

Cochrane Database of Systematic Reviews

2

0 references

publication date

20 January 2003

0 references

published in

0 references

cites work

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

The role of luteinizing hormone in folliculogenesis and ovulation induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Immunohistochemical localization of pituitary gonadotrophins and gonadal steroids confirms the 'two-cell, two-gonadotrophin' hypothesis of steroidogenesis in the human ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Hypersecretion of luteinising hormone, infertility, and miscarriage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

The challenge of meta-analysis and the need to register clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

The challenge of meta-analysis and the need to register clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

Short term use of an LHRH agonist to treat poor responders entering an in-vitro fertilization programme

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003973

7 January 2021

Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003973

Identifiers

DOI

10.1002/14651858.CD003973

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3503952

OpenCitations bibliographic resource ID

3503952

1 reference